No Data
Cantor Fitzgerald Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $75
Cantor Fitzgerald analyst Joshua Schimmer maintains $Crinetics(CRNX.US)$ with a buy rating, and adjusts the target price from $65 to $75.According to TipRanks data, the analyst has a success rate of 5
Baird Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $62
Baird analyst Brian Skorney maintains $Crinetics(CRNX.US)$ with a buy rating, and adjusts the target price from $52 to $62.According to TipRanks data, the analyst has a success rate of 41.7% and a tot
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and BioMarin Pharmaceutical (BMRN)
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $60 to $80
On May 23, major Wall Street analysts update their ratings for $Crinetics(CRNX.US)$, with price targets ranging from $60 to $80.Morgan Stanley analyst Jeffrey Hung maintains with a buy rating, and adj
HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $60 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals with a Buy and maintains $60 price target.
Morgan Stanley Raises Price Target on Crinetics Pharmaceuticals to $70 From $50, Maintains Overweight Rating
Crinetics Pharmaceuticals (CRNX) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $47 to $97.